Loading...
Market
What will be the annual sales figures for Sanofi's tolebrutinib in 2025?
2
Resolution / Starting Odds
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Sanofi's annual financial reports
Story
Sanofi's Tolebrutinib Delays Progressive MS Disability by 31%
Sep 20, 2024, 09:40 AM
Sanofi has announced that its experimental drug, tolebrutinib, has shown promising results in delaying the progression of disability in patients with non-relapsing secondary progressive multiple sclerosis. According to data from a phase 3 trial, tolebrutinib delayed the worsening of the disease by 31%. This development provides hope for patients who currently have no effective treatment options. Sanofi's data indicates a significant 31% delay in disability progression onset.
View original story
Similar markets
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Significantly better • 25%
Moderately better • 25%
Similar • 25%
Worse • 25%
Less than $2 billion • 25%
$2 billion to $3 billion • 25%
$3 billion to $4 billion • 25%
More than $4 billion • 25%
Less than $500 million • 25%
$500 million - $1 billion • 25%
$1 billion - $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $200 million • 25%
$200 million to $400 million • 25%
$400 million to $600 million • 25%
More than $600 million • 25%
